AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Nine species (240 strains) of gram-negative bacilli were studied; 221 were freshly isolated from the urinary and intestinal tracts, wounds and abscesses. Thirteen strains of salmonella and 6 of ...

The following is a summary of “Plasma Lipopolysaccharide-Binding Protein (LBP) Is Induced in Critically Ill Females with Gram ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...